Arteriolar constriction and local renin-angiotensin system in rat microcirculation. 1993

E Vicaut, and X Hou
Laboratoire de Biophysique, Hôpital F. Widal, Paris, France.

Intravital microscopy was used in a preparation of rat cremaster muscle that was isolated from its normal blood supply and externally perfused with a physiological solution, thus allowing exclusion of circulating converting enzyme, renin, and angiotensinogen. The arterioles studied were classified as second-, third-, and fourth-order arterioles with mean diameters of 60.5, 29.9, and 14.8 microns, respectively. Topical administration of 1 nmol/mL angiotensin I or 1 nmol/mL tetradecapeptide renin substrate induced marked vasoconstrictions (i.e., 38.5%, 61.5%, and 90.1% and 25%, 34%, and 88% for second-, third-, and fourth-order arterioles with angiotensin I and tetradecapeptide renin substrate, respectively). The angiotensin converting enzyme inhibitor quinapril significantly inhibited the vasoconstrictions caused by either angiotensin I or tetradecapeptide renin substrate. Almost no vasoconstriction was found when angiotensinogen-rich renin-free plasma containing either 2.45 nmol/mL of angiotensinogen or 1.2 micrograms/mL renin was administered. Conversely, these two compounds induced significant constrictions in cremaster muscle preparations in which normal blood perfusion (and thus circulating renin and angiotensinogen) was left in place. We concluded that, in skeletal muscle, 1) the microvascular network is a very effective site of local angiotensin converting enzyme activity and consequently an important target site of angiotensin converting enzyme inhibitors; 2) the effects of tetradecapeptide renin substrate are very different from those of angiotensinogen from plasma and suggest that a large part of the effect of tetradecapeptide renin substrate was due to its nonspecific hydrolysis; and 3) at the microvascular level, circulating renin and angiotensinogen are more effective in inducing arteriolar constriction, in the presence of their substrate or associated enzyme, than local renin and angiotensinogen.

UI MeSH Term Description Entries
D007703 Peptidyl-Dipeptidase A A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of ANGIOTENSIN I to ANGIOTENSIN II, with increase in vasoconstrictor activity, but no action on angiotensin II. It is also able to inactivate BRADYKININ, a potent vasodilator; and has a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. (From https://www.uniprot.org April 15, 2020). ACE1 Angiotensin-Converting Enzyme 1,ACE1 Protein,Angiotensin Converting Enzyme,Angiotensin Converting Enzyme 1,Antigens, CD143,CD143 Antigens,Dipeptidyl Carboxypeptidase I,Kininase II,Peptidase P,Angiotensin I-Converting Enzyme,Carboxycathepsin,Dipeptidyl Peptidase A,Kininase A,ACE1 Angiotensin Converting Enzyme 1,Angiotensin I Converting Enzyme,Carboxypeptidase I, Dipeptidyl,Peptidyl Dipeptidase A
D008297 Male Males
D008833 Microcirculation The circulation of the BLOOD through the MICROVASCULAR NETWORK. Microvascular Blood Flow,Microvascular Circulation,Blood Flow, Microvascular,Circulation, Microvascular,Flow, Microvascular Blood,Microvascular Blood Flows,Microvascular Circulations
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D009132 Muscles Contractile tissue that produces movement in animals. Muscle Tissue,Muscle,Muscle Tissues,Tissue, Muscle,Tissues, Muscle
D009392 Nephrectomy Excision of kidney. Heminephrectomy,Heminephrectomies,Nephrectomies
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D000803 Angiotensin I A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine

Related Publications

E Vicaut, and X Hou
May 1977, The American journal of physiology,
E Vicaut, and X Hou
July 2015, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology,
E Vicaut, and X Hou
April 1993, American journal of hypertension,
E Vicaut, and X Hou
January 2009, Journal of periodontology,
E Vicaut, and X Hou
June 1977, The American journal of physiology,
E Vicaut, and X Hou
October 2013, Frontiers in endocrinology,
E Vicaut, and X Hou
April 2008, Current hypertension reports,
E Vicaut, and X Hou
January 2015, International journal of clinical and experimental pathology,
Copied contents to your clipboard!